263 related articles for article (PubMed ID: 23644386)
1. Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization.
Salem R; Gilbertsen M; Butt Z; Memon K; Vouche M; Hickey R; Baker T; Abecassis MM; Atassi R; Riaz A; Cella D; Burns JL; Ganger D; Benson AB; Mulcahy MF; Kulik L; Lewandowski R
Clin Gastroenterol Hepatol; 2013 Oct; 11(10):1358-1365.e1. PubMed ID: 23644386
[TBL] [Abstract][Full Text] [Related]
2. Transarterial radioembolization versus chemoembolization for the treatment of hepatocellular carcinoma (TRACE): study protocol for a randomized controlled trial.
Seinstra BA; Defreyne L; Lambert B; Lam MG; Verkooijen HM; van Erpecum KJ; van Hoek B; van Erkel AR; Coenraad MJ; Al Younis I; van Vlierberghe H; van den Bosch MA
Trials; 2012 Aug; 13():144. PubMed ID: 22913492
[TBL] [Abstract][Full Text] [Related]
3. Comparison of health-related quality of life after transarterial chemoembolization and transarterial radioembolization in patients with unresectable hepatocellular carcinoma.
Kirchner T; Marquardt S; Werncke T; Kirstein MM; Brunkhorst T; Wacker F; Vogel A; Rodt T
Abdom Radiol (NY); 2019 Apr; 44(4):1554-1561. PubMed ID: 30311050
[TBL] [Abstract][Full Text] [Related]
4. Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone.
Wang YB; Chen MH; Yan K; Yang W; Dai Y; Yin SS
Qual Life Res; 2007 Apr; 16(3):389-97. PubMed ID: 17111232
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the survival and tolerability of radioembolization in elderly vs. younger patients with unresectable hepatocellular carcinoma.
Golfieri R; Bilbao JI; Carpanese L; Cianni R; Gasparini D; Ezziddin S; Paprottka PM; Fiore F; Cappelli A; Rodriguez M; Ettorre GM; Saltarelli A; Geatti O; Ahmadzadehfar H; Haug AR; Izzo F; Giampalma E; Sangro B; Pizzi G; Notarianni E; Vit A; Wilhelm K; Jakobs TF; Lastoria S;
J Hepatol; 2013 Oct; 59(4):753-61. PubMed ID: 23707371
[TBL] [Abstract][Full Text] [Related]
6. Meta-analysis: adjusted indirect comparison of drug-eluting bead transarterial chemoembolization versus
Ludwig JM; Zhang D; Xing M; Kim HS
Eur Radiol; 2017 May; 27(5):2031-2041. PubMed ID: 27562480
[TBL] [Abstract][Full Text] [Related]
7. Health-related quality of life of patients with intermediate hepatocellular carcinoma after liver resection or transcatheter arterial chemoembolization.
Xie ZR; Luo YL; Xiao FM; Liu Q; Ma Y
Asian Pac J Cancer Prev; 2015; 16(10):4451-6. PubMed ID: 26028113
[TBL] [Abstract][Full Text] [Related]
8. Safety and Efficacy of Transarterial Radioembolization Combined with Chemoembolization for Bilobar Hepatocellular Carcinoma: A Single-Center Retrospective Study.
Kwon JH; Kim GM; Han K; Won JY; Kim MD; Lee DY; Lee J; Choi W; Kim YS; Kim DY; Han KH
Cardiovasc Intervent Radiol; 2018 Mar; 41(3):459-465. PubMed ID: 29067511
[TBL] [Abstract][Full Text] [Related]
9. Transarterial chemoembolization and yittrium-90 for liver cancer and other lesions.
Minocha J; Salem R; Lewandowski RJ
Clin Liver Dis; 2014 Nov; 18(4):877-90. PubMed ID: 25438288
[TBL] [Abstract][Full Text] [Related]
10. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
11. Prospective evaluation of patients with early-/intermediate-stage hepatocellular carcinoma with disease progression following arterial locoregional therapy: candidacy for systemic treatment or clinical trials.
Memon K; Kulik L; Lewandowski RJ; Gupta R; Ryu RK; Miller FH; Vouche M; Atassi R; Ganger D; Mulcahy MF; Salem R
J Vasc Interv Radiol; 2013 Aug; 24(8):1189-1197.e2. PubMed ID: 23474327
[TBL] [Abstract][Full Text] [Related]
12. Radioembolization results in longer time-to-progression and reduced toxicity compared with chemoembolization in patients with hepatocellular carcinoma.
Salem R; Lewandowski RJ; Kulik L; Wang E; Riaz A; Ryu RK; Sato KT; Gupta R; Nikolaidis P; Miller FH; Yaghmai V; Ibrahim SM; Senthilnathan S; Baker T; Gates VL; Atassi B; Newman S; Memon K; Chen R; Vogelzang RL; Nemcek AA; Resnick SA; Chrisman HB; Carr J; Omary RA; Abecassis M; Benson AB; Mulcahy MF
Gastroenterology; 2011 Feb; 140(2):497-507.e2. PubMed ID: 21044630
[TBL] [Abstract][Full Text] [Related]
13. Impact of interventions and tumor stage on health-related quality of life in patients with hepatocellular carcinoma.
Wehling C; Hornuss D; Schneider P; Springfeld C; Hoffmann K; Chang DH; Naumann P; Mieth M; Longerich T; Kratochwil C; Mehrabi A; Gauss A; Weiss KH; Pfeiffenberger J
J Cancer Res Clin Oncol; 2019 Nov; 145(11):2761-2769. PubMed ID: 31428932
[TBL] [Abstract][Full Text] [Related]
14. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
[TBL] [Abstract][Full Text] [Related]
15. Transarterial bland versus chemoembolization for hepatocellular carcinoma: rethinking a gold standard.
Massarweh NN; Davila JA; El-Serag HB; Duan Z; Temple S; May S; Sada YH; Anaya DA
J Surg Res; 2016 Feb; 200(2):552-9. PubMed ID: 26507276
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib with TACE improves the survival of hepatocellular carcinoma patients with more than 10 cm tumor: a single-center retrospective study.
Aktas G; Kus T; Emin Kalender M; Kervancioglu S; Sevinc A; Kul S; Camci C
J BUON; 2017; 22(1):150-156. PubMed ID: 28365948
[TBL] [Abstract][Full Text] [Related]
17. Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma.
Kolligs FT; Bilbao JI; Jakobs T; Iñarrairaegui M; Nagel JM; Rodriguez M; Haug A; D'Avola D; op den Winkel M; Martinez-Cuesta A; Trumm C; Benito A; Tatsch K; Zech CJ; Hoffmann RT; Sangro B
Liver Int; 2015 Jun; 35(6):1715-21. PubMed ID: 25443863
[TBL] [Abstract][Full Text] [Related]
18. Transarterial radioembolization in patients with hepatocellular carcinoma of intermediate B2 substage.
Cappelli A; Sangro P; Mosconi C; Deppe I; Terzi E; Bilbao JI; Rodriguez-Fraile M; De Benedittis C; Ricke J; Golfieri R; Sangro B
Eur J Nucl Med Mol Imaging; 2019 Mar; 46(3):661-668. PubMed ID: 30209522
[TBL] [Abstract][Full Text] [Related]
19. Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study.
Eltawil KM; Berry R; Abdolell M; Molinari M
HPB (Oxford); 2012 May; 14(5):341-50. PubMed ID: 22487072
[TBL] [Abstract][Full Text] [Related]
20. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study.
Sacco R; Bertini M; Petruzzi P; Bertoni M; Bargellini I; Bresci G; Federici G; Gambardella L; Metrangolo S; Parisi G; Romano A; Scaramuzzino A; Tumino E; Silvestri A; Altomare E; Vignali C; Capria A
World J Gastroenterol; 2009 Apr; 15(15):1843-8. PubMed ID: 19370781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
